A Phase 3 interventional study of Aclidinium bromide/formoterol Fixed-Dose Combination and Aclidinium bromide in COPD, sponsored by AstraZeneca. Completed at 75 sites in 5 countries. Open to participants aged 40 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-03-26.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. aclidinium bromide · Pulmonary Disease, Chronic Obstructive.
Among the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive, this one is the 4th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2017, is one of 19 in phase 3, and was the 27th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →None of the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →
aclidinium bromide: first FDA approval 2012 (TUDORZA PRESSAIR), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,625 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 561 across the 27 interventional studies. Of the 27 that completed or were terminated, 23 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 4 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 17th largest by enrollment of the 194 interventional ones that give a count, is one of 14 that started in 2017, is one of 76 in phase 3, and was the 198th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstructive Pulmonary Disease (COPD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aclidinium bromide 400μg/Formoterol fumarate 12 μg
Drug: Aclidinium bromide/formoterol Fixed-Dose Combination
Aclidinium bromide 400 μg
Drug: Aclidinium bromide
Formoterol fumarate 12 μg
Drug: Formoterol Fumarate
Placebo
Drug: Placebo
Drug pages: Aclidinium bromide · Formoterol
Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair
Inhaled Aclidinium bromide 400 μg, twice per day via Genuair
Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler
Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler
Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1)
Change from baseline in 1-hour morning post-dose FEV1 of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg compared to Aclidinium bromide at Week 24. Baseline was defined as the average of the two FEV1 values measure prior to the administration of the first dose of the IP at randomisation visit. If one of the two values was missing, the available one was used as baseline. If both values were missing, the screening pre-bronchodilator value was used. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.
Time frame: Week 24, 1-hour morning post-dose
Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol Fumarate
Change from baseline in morning pre-dose (trough) FEV1 of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg compared to Formoterol fumarate 12 μg at Week 24. Morning pre-dose (trough) FEV1 was defined as the average of the two FEV1 values at morning pre-dose of IP at Week 24. If one value was missing, the remaining was used as the trough value. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.
Time frame: Week 24, morning pre-dose (trough)
Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide
Change from baseline in morning pre-dose (trough) FEV1 of Aclidinium bromide 400 μg compared to placebo at Week 24. Morning pre-dose (trough) FEV1 was defined as the average of the two FEV1 values at morning pre-dose of IP at Week 24. If one value was missing, the remaining was used as the trough value. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.
Time frame: Week 24, morning pre-dose (trough)
Change From Baseline in Peak FEV1
Change from baseline in peak FEV1 of Aclidinium bromide 400 μg compared to placebo at week 24. Peak FEV1 was the highest value recorded at Week 24 after morning IP intake. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.
Time frame: Week 24, peak
Improvements Transition Dyspnoea Index (TDI) Focal Score
Improvements TDI focal score of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg and Aclidinium bromide 400μg compared to placebo at week 24. Transition Dyspnoea Index (TDI) measures severity of breathlessness in symptomatic patients. An impairment severity score is assigned for three components: functional impairment; magnitude of task and magnitude of effort. Focal scores is derived as the sum of individual component scores. TDI focal score ranges from -9 to +9, with negative values indicating a worsening in dyspnoea, 0 showing no change from baseline and positive values associated with a post-baseline improvement. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.
Time frame: Week 24
Change From Baseline in St Georges Respiratory Questionnaire (SGRQ) Total Score
Change from baseline in SGRQ total score of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg and Aclidinium bromide 400μg compared to placebo at week 24. St. George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life and perceived well-being. It is composed of 50 items split into 17 parts, from which 3 dimension scores on Symptoms, Activity and Impact are derived. A total score utilising responses to all items can also be derived to assess the overall impact of COPD on quality of life. SGRQ dimension and total scores range from 0 to 100, with higher scores indicating a worse possible health status. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.
Time frame: Week 24
The study was conducted at 81 study centers in 5 countries China(50), India (15), Philippines (8), Taiwan (3) and Vietnam (5) between 02 February 2017 and 14 April 2022
| Milestone | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo |
|---|---|---|---|---|
| Started | 265 | 267 | 265 | 269 |
| Received treatment | 263 | 266 | 264 | 269 |
| Received treatment with a baseline fev1 | 262 | 265 | 259 | 267 |
| Completed treatment | 243 | 247 | 230 | 230 |
| Completed | 244 | 248 | 233 | 235 |
| Not completed | 21 | 19 | 32 | 34 |
| Withdrew: Adverse event | 3 | 4 | 1 | 3 |
| Withdrew: Progressive disease | 2 | 0 | 5 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 3 | 3 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 11 | 13 | 15 | 21 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 |
| Withdrew: Other | 4 | 1 | 6 | 4 |
| Withdrew: Due to covid-19 pandemic | 0 | 1 | 0 | 0 |
Change from baseline in 1-hour morning post-dose FEV1 of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg compared to Aclidinium bromide at Week 24. Baseline was defined as the average of the two FEV1 values measure prior to the administration of the first dose of the IP at randomisation visit. If one of the two values was missing, the available one was used as baseline. If both values were missing, the screening pre-bronchodilator value was used. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.
| Litres | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo |
|---|---|---|---|---|
| Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) | 0.248 ± 0.013 | 0.156 ± 0.013 | 0.138 ± 0.013 | -0.050 ± 0.013 |
Change from baseline in morning pre-dose (trough) FEV1 of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg compared to Formoterol fumarate 12 μg at Week 24. Morning pre-dose (trough) FEV1 was defined as the average of the two FEV1 values at morning pre-dose of IP at Week 24. If one value was missing, the remaining was used as the trough value. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.
| Litres | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol Fumarate | 0.081 ± 0.014 | 0.050 ± 0.014 | -0.004 ± 0.014 | -0.084 ± 0.014 |
Change from baseline in morning pre-dose (trough) FEV1 of Aclidinium bromide 400 μg compared to placebo at Week 24. Morning pre-dose (trough) FEV1 was defined as the average of the two FEV1 values at morning pre-dose of IP at Week 24. If one value was missing, the remaining was used as the trough value. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.
| Litres | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide | 0.081 ± 0.014 | 0.050 ± 0.014 | -0.004 ± 0.014 | -0.084 ± 0.014 |
Change from baseline in peak FEV1 of Aclidinium bromide 400 μg compared to placebo at week 24. Peak FEV1 was the highest value recorded at Week 24 after morning IP intake. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.
| Litres | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Peak FEV1 | 0.324 ± 0.013 | 0.225 ± 0.013 | 0.191 ± 0.014 | 0.008 ± 0.014 |
Improvements TDI focal score of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg and Aclidinium bromide 400μg compared to placebo at week 24. Transition Dyspnoea Index (TDI) measures severity of breathlessness in symptomatic patients. An impairment severity score is assigned for three components: functional impairment; magnitude of task and magnitude of effort. Focal scores is derived as the sum of individual component scores. TDI focal score ranges from -9 to +9, with negative values indicating a worsening in dyspnoea, 0 showing no change from baseline and positive values associated with a post-baseline improvement. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.
| Units on a scale | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo |
|---|---|---|---|---|
| Improvements Transition Dyspnoea Index (TDI) Focal Score | 2.9 ± 0.2 | 2.6 ± 0.2 | 2.4 ± 0.2 | 2.1 ± 0.3 |
Change from baseline in SGRQ total score of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg and Aclidinium bromide 400μg compared to placebo at week 24. St. George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life and perceived well-being. It is composed of 50 items split into 17 parts, from which 3 dimension scores on Symptoms, Activity and Impact are derived. A total score utilising responses to all items can also be derived to assess the overall impact of COPD on quality of life. SGRQ dimension and total scores range from 0 to 100, with higher scores indicating a worse possible health status. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.
| Units on a scale | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo |
|---|---|---|---|---|
| Change From Baseline in St Georges Respiratory Questionnaire (SGRQ) Total Score | -8.7 ± 1.2 | -7.6 ± 1.2 | -7.2 ± 1.2 | -4.7 ± 1.2 |
Collected over From time of signature of informed consent throughout the treatment period and including the follow-up period (2 weeks after last IP dose), on average 26 weeks. Only treatment-emergent AEs are reported in the tables below.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AB/FF 400/12 μg | 0/263 (0%) | 19/263 (7.2%) | 53/263 (20.2%) |
| AB 400 μg | 0/266 (0%) | 21/266 (7.9%) | 44/266 (16.5%) |
| FF 12 μg | 1/264 (0.4%) | 26/264 (9.8%) | 54/264 (20.5%) |
| Placebo | 2/269 (0.7%) | 21/269 (7.8%) | 55/269 (20.4%) |
| Event | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo |
|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 9/263 | 6/266 | 10/264 | 7/269 |
| PneumoniaInfections and infestations | 2/263 | 3/266 | 5/264 | 4/269 |
| Acute myocardial infarctionCardiac disorders | 0/263 | 0/266 | 2/264 | 0/269 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 0/263 | 2/266 | 0/264 | 0/269 |
| Lower respiratory tract infectionInfections and infestations | 1/263 | 0/266 | 0/264 | 1/269 |
| Postoperative wound infectionInfections and infestations | 1/263 | 0/266 | 0/264 | 0/269 |
| SepsisInfections and infestations | 1/263 | 0/266 | 0/264 | 0/269 |
| Benign neoplasm of adrenal glandNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/263 | 0/266 | 0/264 | 0/269 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/263 | 0/266 | 0/264 | 0/269 |
| Cerebral arteriosclerosisNervous system disorders | 1/263 | 0/266 | 0/264 | 0/269 |
| Event | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo |
|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 25/263 | 21/266 | 33/264 | 35/269 |
| Upper respiratory tract infectionInfections and infestations | 31/263 | 25/266 | 24/264 | 24/269 |
Safety population comprising all participants randomised to a treatment group who received at least one dose of double-blind investigational treatment (Safety Analysis Set).
| Age, Continuous(Years) | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 65.3 ± 7.1 | 65.4 ± 6.8 | 65.4 ± 7.6 | 64.9 ± 6.9 | 65.2 ± 7.1 |
| Sex/Gender, Customized(Participants) | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo | Total |
|---|---|---|---|---|---|
| Male | 256 | 254 | 251 | 256 | 1017 |
| Female | 7 | 12 | 13 | 13 | 45 |
| Race (NIH/OMB)(Participants) | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 263 | 266 | 264 | 269 | 1062 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo | Total |
|---|---|---|---|---|---|
| Chinese | 186 | 186 | 187 | 188 | 747 |
| Taiwanese | 3 | 3 | 4 | 4 | 14 |
| Vietnamese | 10 | 10 | 9 | 10 | 39 |
| Indian | 35 | 37 | 35 | 37 | 144 |
| Filipino | 29 | 30 | 29 | 30 | 118 |
| Pre-bronchodilator FEV1 at screening(Litres) | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 1.187 ± 0.404 | 1.192 ± 0.385 | 1.199 ± 0.415 | 1.212 ± 0.383 | 1.197 ± 0.396 |
| Post-bronchodilator FEV1 at screening(Litres) | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 1.356 ± 0.420 | 1.363 ± 0.390 | 1.366 ± 0.447 | 1.385 ± 0.408 | 1.367 ± 0.416 |
| Baseline FEV1(Litres) | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 1.182 ± 0.415 | 1.178 ± 0.381 | 1.169 ± 0.413 | 1.184 ± 0.399 | 1.178 ± 0.402 |
| Smoking status(Participants) | AB/FF 400/12 μg | AB 400 μg | FF 12 μg | Placebo | Total |
|---|---|---|---|---|---|
| Current smoker | 84 | 85 | 86 | 85 | 340 |
| Former smoker | 179 | 181 | 178 | 184 | 722 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Feb 2017 to primary completion in Apr 2022, 62 months.
Results were first posted in Mar 2025, 2 years 11 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 62 months is above that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aclidinium bromide · Formoterol
Pulmonary Disease, Chronic Obstructive →